MDxHealth SA ADR
$ 0.64
-2.88%
02 Jun - close price
- Market Cap 33,530,800 USD
- Current Price $ 0.64
- High / Low $ 0.69 / 0.61
- Stock P/E N/A
- Book Value -0.39
- EPS -0.65
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -24.40 %
- 52 Week High 5.33
- 52 Week Low 0.51
About
MDxHealth SA is a pioneering biotechnology company dedicated to advancing precision diagnostics in cancer management, primarily targeting prostate and bladder cancers. Its flagship product, ConfirmMDx for Prostate Cancer, has garnered significant attention for its clinical efficacy and strong market presence. With the increasing emphasis on personalized medicine and the rising demand for targeted cancer therapies, MDxHealth is well-positioned to expand its innovative diagnostic offerings, aiming to meet critical unmet needs in oncology and enhance patient outcomes while pursuing sustainable growth.
Analyst Target Price
$3.90
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-02-26 | 2025-11-12 | 2025-08-05 | 2025-05-14 | 2025-02-26 | 2024-11-06 | 2024-08-21 | 2024-05-01 | 2024-03-06 | 2023-11-07 | 2023-08-23 |
| Reported EPS | -0.17 | -0.17 | -0.16 | -0.14 | -0.19 | -0.14 | -0.4 | -0.42 | -0.31 | -0.39 | -0.4 | -0.3 |
| Estimated EPS | -0.098 | -0.1251 | -0.17 | -0.12 | -0.13 | -0.19 | -0.25 | -0.26 | -0.3 | -0.11 | -0.19 | -0.22 |
| Surprise | -0.072 | -0.0449 | 0.01 | -0.02 | -0.06 | 0.05 | -0.15 | -0.16 | -0.01 | -0.28 | -0.21 | -0.08 |
| Surprise Percentage | -73.4694% | -35.8913% | 5.8824% | -16.6667% | -46.1538% | 26.3158% | -60% | -61.5385% | -3.3333% | -254.5455% | -110.5263% | -36.3636% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXH
2026-05-28 20:10:20
Brendan O’Connell, VP of Finance and Accounting at MDxHealth SA (MDXH), has filed an initial Form 3 statement of beneficial ownership. This filing establishes his insider status with the company but reports no purchases, sales, or other transactions. The document indicates that he beneficially owns no securities as of the filing date.
2026-05-21 06:41:03
Mdxhealth (MDXH) is strategically refocusing on its high-growth prostate cancer franchise, as revealed in its Q1 earnings call. The company is exiting its Resolve UTI business due to reimbursement uncertainties and concentrating on core oncology assets, targeting $110 million to $115 million in revenue for 2026 from this segment. Despite facing near-term challenges like margin pressure, integration costs, and a potential Medicare recoupment of up to $10.4 million, Mdxhealth aims for durable growth through AI initiatives, ExoDx synergies, and a streamlined portfolio.
2026-05-20 09:39:45
MDxHealth reported a significant Q1 2026 earnings miss, with EPS of -$0.17 and revenue of $27.4 million falling short of forecasts, leading to a sharp stock price decline. The company is discontinuing its Resolve UTI business due to reimbursement issues but plans to focus on its core prostate cancer diagnostics, anticipating 20-26% year-over-year revenue growth in that segment for 2026. MDxHealth also faces an ongoing legal dispute with Novitas regarding $10.4 million in historical Resolve claims.
2026-05-20 06:00:00
MDxHealth reported a significant earnings and revenue miss for Q1 2026, with EPS of -$0.17 against a forecasted -$0.15, and revenue of $27.4 million versus an anticipated $31.12 million. This led to a sharp stock price decline and prompted the company to discontinue its Resolve UTI business due to reimbursement issues and an ongoing legal dispute with Novitas. Despite these challenges, MDxHealth plans to focus on its core prostate cancer diagnostics, integrate AI, and projects a 20-26% year-over-year revenue growth for its core cancer business in 2026.
2026-05-18 10:39:27
MDxHealth (MDXH) reported a Q1 2026 loss of US$8.9 million despite revenue growth to US$27.4 million, maintaining investor focus on profitability concerns. While revenue has increased, the company's net losses have remained consistently high, leading to a widening trailing 12-month loss and negative shareholders' equity, which reinforces a bearish outlook despite the stock trading at a deep discount to fair value and industry peers. The analysis highlights the challenge for MDxHealth to translate revenue growth into actual profits in the near term.
2026-05-16 21:10:23
MDxHealth SA, a molecular diagnostics specialist for urologic cancers, recently completed a capital raise in early 2025 and is intensifying its focus on the US market. The company develops and commercializes tests for prostate and other urologic cancers, aiming to guide treatment decisions and distinguish aggressive from indolent disease. Despite its strategic focus on the US and continuous efforts in clinical validation and reimbursement, MDxHealth remains a volatile small-cap stock due to market sentiment shifts and the competitive diagnostics landscape.
